This content is only available in English

Gabriele Multhoff - Experimental Radiation Oncology and Radiobiology

Research Focus

One of the focus areas of Prof. Gabriele Multhoff’s research work is the development of innovative cell-, molecule- and antibody-based targeted immunotherapies based on heat shock proteins (SFB 824: in vivo imaging). The aim is to combine these new therapeutic approaches with conventional radiation therapy and chemotherapy as a theragnostic. Her current research work has led to a randomized, multicenter clinical phase II study entitled “Targeted NK cell-based adjuvant immunotherapy for the treatment of patients with non-small cell lung carcinoma (NSCLC) after radiochemotherapy” funded by the German Federal Ministry of Education and Research (BMBF). To stratify patients who most likely will benefit from Hsp70-targeting therapies, her group established a novel screening test (lipHsp70 ELISA, patent) to quantify exosomal, tumor-derived Hsp70 and a method to isolate circulating tumor cells (CTCs) after mesenchymal transition in the blood of patients. Hsp70 in liquid biopsies provides a promising biomarker for viable tumor mass in different tumor entities and CTCs in the blood are presently evaluated as valuable tools for prediction of clinical responses and therapy resistance of cancer. Presently anti-Hsp70 CART/NK cells are developed for preclinical and clinical application (cooperation Sebastian Kobold LMU).

Prof. Multhoff’s research interests also include the application of novel in vivo imaging techniques such as intraoperative, fluorescence molecular tomography (FMT), multispectral optoacoustic tomography (MSOT) and PET/CT in small animals after CT-guided irradiation of tumors using the small animal radiation research platform SARRP (DFG INST411/37-1 FUGG) and the analysis of cell-based immunosupportive, immunosuppressive metabolic  mechanisms in the tumor and  TME including primary endothelial cells after exposure to radiation, as well as the development of innovative nanoparticle-based theragostica.

After studying biology at LMU Munich, Gabriele Multhoff completed her Ph.D. in 1990, having conducted research in the field of immunology. While she was working toward her postdoctoral teaching qualification (habilitation), which she acquired in 1998, she was supported by a Möllemann Habilitation stipend. In 2002 she became a professor of “Experimental Hematology” at the University Hospital Regensburg before being appointed professor for “Experimental Radiooncology and Radiation Biology” at Klinikum rechts der Isar at TUM in 2007. She holds a Zweitmitgliedschaft at the „Wissenschaftszentrum Weihenstephan“ in Freising. In 2004 she became “consultant immunologist”. Between 2007 and 2009 she was president of the “Cell Stress Society International” (CSSI). Prof. Multhoff is founder and CSO of the biotech company multimmune GmbH and holds more than 15 patents. She is a commissioner of the German Academic Exchange Service (DAAD) and the EU, as well as a member of numerous professional and scientific associations.

  • ISOTT Preis (International Society on Oxygen Transport to Tissue) (2018)
  • CESAR Preis (Central European Society for Anticancer Drug Research) (2015)
  • Paula und Richard von Hertwig Preis der Helmholtzgemeinschaft (1998)
  • ESHO-BSD Preis (European Society of Hyperthermic Oncology) (1996)
  • Young Investigator Award, VII International Congress on Hyperthermic Oncology (ICHO), (Society for Thermal Medicine) (1996)

Bashiri Dezfouli, A., Yazdi, M., Benmebarek, M.R., Schwab, M., Michaelides, S., Miccheche, A., Geerts, D., Stangl, S., Klapproth, S., Mohagheghi, F., Wagner, E., Kobold, S., Multhoff, G. (2022) CAR T cells targeting membrane Hsp70 mimic the cytolytic activity of stimulated NK cells. Front Immunol accepted

Fan, H., Sievert, W., Hofmann, J., Keppler, S.J., Steiger, K., Puig-Bosch, X., Haller, B., Rammes, G., Multhoff, G. (2022). Partial-Brain Radiation-Induced Microvascular Cognitive Impairment in Juvenile Murine Unilateral Hippocampal Synaptic Plasticity. Int J Radiat Oncol Biol Phys 112, 747-758.

Schwab, M., Thunborg, K., Azimzadeh, O., von Toerne, C., Werner, C., Shevtsov, M., Di Genio, T., Zdralevic, M., Pouyssegur, J., Renner, K., Kreutz, M., Multhoff, G. (2021). Targeting Cancer Metabolism Breaks Radioresistance by Impairing the Stress Response. Cancers (Basel) 13,

Werner, C., Stangl, S., Salvermoser, L., Schwab, M., Shevtsov, M., Xanthopoulos, A., Wang, F., Dezfouli, A.B., Tholke, D., Ostheimer, C., Medenwald, D., Windberg, M., Bache, M., Schlapschy, M., Skerra, A., Multhoff, G. (2021). Hsp70 in Liquid Biopsies-A Tumor-Specific Biomarker for Detection and Response Monitoring in Cancer. Cancers (Basel) 13,

Multhoff, G., Seier, S., Stangl, S., Sievert, W., Shevtsov, M., Werner, C., Pockley, A.G., Blankenstein, C., Hildebrandt, M., Offner, R., Ahrens, N., Kokowski, K., Hautmann, M., Rodel, C., Fietkau, R., Lubgan, D., Huber, R., Hautmann, H., Duell, T., Molls, M., Specht, H., Haller, B., Devecka, M., Sauter, A., Combs, S.E. (2020). Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clin Cancer Res 26, 5368-5379.

Kokowski, K., Stangl, S., Seier, S., Hildebrandt, M., Vaupel, P., Multhoff, G. (2019). Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study. Strahlenther Onkol 195, 352-361.

Stangl, S., Tontcheva, N., Sievert, W., Shevtsov, M., Niu, M., Schmid, T.E., Pigorsch, S., Combs, S.E., Haller, B., Balermpas, P., Rodel, F., Rodel, C., Fokas, E., Krause, M., Linge, A., Lohaus, F., Baumann, M., Tinhofer, I., Budach, V., Stuschke, M., Grosu, A.L., Abdollahi, A., Debus, J., Belka, C., Maihofer, C., Monnich, D., Zips, D., Multhoff, G. (2018). Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 142, 1911-1925.

Stangl, S., Tei, L., De Rose, F., Reder, S., Martinelli, J., Sievert, W., Shevtsov, M., Ollinger, R., Rad, R., Schwaiger, M., D'Alessandria, C., Multhoff, G. (2018). Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[(89)Zr] for Tumor-Specific PET/CT Imaging. Cancer Res 78, 6268-6281.

Stangl, S., Varga, J., Freysoldt, B., Trajkovic-Arsic, M., Siveke, J.T., Greten, F.R., Ntziachristos, V., Multhoff, G. (2014). Selective in vivo imaging of syngeneic, spontaneous, and xenograft tumors using a novel tumor cell-specific hsp70 peptide-based probe. Cancer Res 74, 6903-12.

Stangl, S., Gehrmann, M., Riegger, J., Kuhs, K., Riederer, I., Sievert, W., Hube, K., Mocikat, R., Dressel, R., Kremmer, E., Pockley, A.G., Friedrich, L., Vigh, L., Skerra, A., Multhoff, G. (2011). Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A 108, 733-8.

Prof. Dr. Gabriele Multhoff
Technical University of Munich
School of Medicine
Clinic and Polyclinic for Radiation Oncology and Radiotherapy

Anett Lange
Phone:+ 49 89 4140 7678